Networking with fibrinogen: A prerequisite for fibroblast growth factor-2 (FGF-2)-stimulated tumor growth?

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 174-175

  Dahl, Morten ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOT; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; HUMAN; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; WILD TYPE;

CELL PROLIFERATION; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOPLASMS;

EID: 37549055804     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02756.x     Document Type: Note

References (16)

1. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
2. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 2001; 936: 406-25.
3. Staton CA, Brown NJ, Lewis CE. The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin Biol Ther 2003; 3: 1105-20.
4. Biggerstaff JP, Weidow B, Vidosh J, Dexheimer J, Patel S, Patel P. Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: Implications for cancer metastasis. Thromb J 2006; 4: 12.
5. Cardinali M, Uchino R, Chung SI. Interaction of fibrinogen with murine melanoma cells: Covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells. Cancer Res 1990; 50: 8010-6.
6. Lee SY, Park LO, Suk SH. Role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells. Oncology 2000; 59: 238-44.
7. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-85.
8. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-9.
9. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 6966-72.
10. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW. Fibrinogen synthesized by cancer cells augments the proliferative effect of FGF-2. J Thromb Haemost 2008; 6: 176-83.
11. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. Blood 2004; 104: 3635-41.
12. Sahni A, Khorana AA, Baggs RB, Peng H, Francis CW. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Blood 2006; 107: 126-31.
13. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96: 3772-8.
14. Yu PJ, Ferrari G, Galloway AC, Mignatti P, Pintucci G. Basic fibroblast growth factor (FGF-2): The high molecular weight forms come of age. J Cell Biochem 2007; 100: 1100-8.
15. Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000; 83: 736-41.
16. Seeholzer N, Thurlimann B, Koberle D, Hess D, Korte W. Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: Results on clinical response, transforming growth factor-beta1 and fibrin monomer in a phase II study. Blood Coagul Fibrinolysis 2007; 18: 415-23.